<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743847</url>
  </required_header>
  <id_info>
    <org_study_id>A3051100</org_study_id>
    <nct_id>NCT00743847</nct_id>
  </id_info>
  <brief_title>A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia</brief_title>
  <official_title>A Phase 2 6-Week, Double-Blind, Placebo-Controlled, Multicenter Trial Of Varenicline Tartrate (CP-526,555) For Cognitive Impairment In Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this protocol is to assess the efficacy of two dose strengths of
      varenicline (0.5 mg BID and 1mg BID) as adjunctive treatment for cognitive impairment in
      symptomatically stable outpatient schizophrenic subjects who are receiving treatment with
      atypical antipsychotic medications.

      A secondary objective is to evaluate the safety and tolerability of two doses of varenicline
      in symptomatically stable schizophrenic subjects who are receiving treatment with atypical
      antipsychotic medications.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">November 2009</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CNS Vital Signs Cognition Battery (CNS-VS-M) normed composite score</measure>
    <time_frame>screening, wk -1, baseline, wk 1,3,6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CNS-VS-M un-normed composite score</measure>
    <time_frame>screening, wk-1,baseline,wk1,3,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS-VS-M un-normed and normed domain scores</measure>
    <time_frame>screening, wk-1,baseline, wk1,3,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of California San Diego Performance Skills Assessment Brief (UPSA-B) total score</measure>
    <time_frame>baseline, wk 1,3,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Item for Cognitive Impairment-Clinician and Patient Versions (SICI-CV; SICI-PV)</measure>
    <time_frame>baseline, wk6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Improvement in Cognition Clinician and Patient Versions (GIC-CV;GIC-PV)</measure>
    <time_frame>wk 1,3,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments, including adverse events, electrocardiographic assessments, neuropsychiatric assessments (performed weekly), physical exam, and laboratory measures</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>varenicline 0.5 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>varenicline 1mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.</description>
    <arm_group_label>varenicline 0.5 mg BID</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.</description>
    <arm_group_label>varenicline 1mg BID</arm_group_label>
    <other_name>Chantix, Champix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a current diagnosis of schizophrenia

          -  Subjects must be on ongoing maintenance antipsychotic monotherapy or combination
             therapy with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or
             paliperidone.

          -  Evidence of stable symptomatology â‰¥3 months (eg, no hospitalizations for
             schizophrenia, no increase in level of psychiatric care due to worsening of symptoms
             of schizophrenia).

        Exclusion Criteria:

          -  Subjects with a current DSM-IV axis I diagnosis other than schizophrenia.

          -  Current treatment with conventional antipsychotics (e.g. fluphenazine, haloperidol) or
             clozapine, or the use of adjunctive anticholinergic treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3051100&amp;StudyName=A%206-Week%20Multicenter%20Trial%20Of%20Varenicline%20Tartrate%20For%20Cognitive%20Impairment%20In%20Subjects%20With%20Schizophrenia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <last_update_submitted>February 20, 2009</last_update_submitted>
  <last_update_submitted_qc>February 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>schizophrenia, treatment, cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

